SCYNEXIS Stock

SCYNEXIS Retained Earnings

The Retained Earnings of SCYNEXIS (SCYX) as of Aug 16, 2026 is -376.54 M USD. In the previous year, Retained Earnings was -355.25 M USD — a change of 5.99% (lower).

Retained Earnings

-376.54 MUSD

YoY

5.99%

Last updated:

Retained Earnings of SCYNEXIS is 2026 -376.54 M USD. Retained Earnings of SCYNEXIS was 2025 -355.25 M USD. It decreases by 5.99% lower compared to the previous year.
Access this data via the Eulerpool API

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCYNEXIS stock

Retained Earnings of SCYNEXIS is -376.54 M USD in 2026.

Retained Earnings of SCYNEXIS changed from -355.25 M USD to -376.54 M USD, representing a 5.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's SCYNEXIS historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — SCYNEXIS

All Key Metrics — SCYNEXIS